CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 51 enrolled
Drug / intervention
diacerein 1% ointmentdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03389308
NCT03389308Phase 2Completed
CompareCT.gov

An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex (EBS)

Castle Creek Pharmaceuticals, LLC·interventional·Posted Jan 3, 2018·Updated Sep 16, 2020

In Brief

A Phase 2 clinical trial evaluating diacerein 1% ointment for Epidermolysis Bullosa and Epidermolysis Bullosa Simplex. Completed, enrolled 51 participants across 3 sites.

Detailed Summary

The primary objective of this study is to evaluate the long term safety and tolerability of diacerein 1% ointment for 2 treatment cycles in subjects with EBS that previously participated in the CCP-020-301 or the CCP-020-101 studies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpidermolysis Bullosa, Epidermolysis Bullosa Simplex
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 3, 2018
Enrollment StartDec 1, 2017
Primary CompletionApr 17, 2020
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 8.5 years ago

Interventions

diacerein 1% ointmentdrug

Topically apply study medication to lesions identified by the Investigator that require. treatment